EndPoints
Endpoints News is a B2B media publication delivering specialized business news, analysis, and data products covering the biotechnology and pharmaceutical industries, serving biotech and pharma professionals, investors, and corporate strategy teams globally. A majority stake was acquired by the Financial Times in 2025 for its FT Specialist division.
- Company typePrivate
- Founded1999
- HeadquartersBedford, United States
- Headcount11–50
- GTM typeB2B
- OfferingDigital Commerce or Content
What EndPoints does
Endpoints News is a privately held B2B media publication founded in 1999 that delivers specialized business news and analysis for the biotechnology and pharmaceutical industries. Operating from Lawrence, Kansas, at the Bioscience and Technology Business Center at the University of Kansas, the company has built a multi-channel content platform organized around 24 editorial channels covering topics such as R&D, FDA+, Deals, Financing, Pharma, and Manufacturing, alongside 12 topic-specific hubs focused on emerging verticals including AI drug discovery, antibody-drug conjugates, CRISPR and gene editing, GLP-1 obesity drugs, drug pricing and the IRA, and China biotech. In 2025, the Financial Times acquired a majority stake for its FT Specialist division, placing Endpoints within a global portfolio of professional information services and validating the publication's standing in the biopharma business media sector. The founder Arsalan Arif continues as Publisher and Founder, and the company employs between 11 and 50 people.
The core product is the Endpoints News website, supplemented by a portfolio of adjacent products including Endpoints Webinars, the Signal biopharma sentiment index, an IPO Tracker, a Biopharma Jobs board, Endpoints Events, and Endpoints Studio, an integrated advertising and sponsored content platform. Distribution occurs through the website, email newsletters, and event channels, with a content-led go-to-motion targeting biotech and pharma professionals as the primary segment, followed by biotech investors and analysts and pharma corporate strategy teams. The website is organized for SEO-driven organic discovery across specialized industry queries.
Endpoints generates revenue through three primary streams: recurring subscriptions consistent with a subscription-first B2B publishing model, sponsored content and advertising sold through Endpoints Studio to pharma and biotech marketing clients, and fee-generating webinars and events. The company follows a vertical segmentation approach, and specific pricing for subscriptions and services is not publicly disclosed. No enterprise anchor customers are identified in available sources, and the customer base is broadly distributed across the global biotech and pharma professional audience.
EndPoints firmographics
Firmographics- Name
- EndPoints
- Legal name
- Endpoints News
- Website
- https://endpts.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Endpoints News is a B2B media publication delivering specialized business news, analysis, and data products covering the biotechnology and pharmaceutical industries, serving biotech and pharma professionals, investors, and corporate strategy teams globally. A majority stake was acquired by the Financial Times in 2025 for its FT Specialist division.
- Ownership category
- akta.pro rank
EndPoints industry classification
Industry- Product category
- Biopharma Trade Media
- NAICS
- Periodical Publishers (51312), Periodical Publishers (513120)
- SIC
- Newspapers: Publishing Or Publishing & Printing (2711), Periodicals: Publishing Or Publishing & Printing (2721)
- akta.pro primary industry
- Business, Financial & Trade News Publishers (MPAJADAC)
- akta.pro secondary industry
- Newsletters & Email-Based News Publishers (B2B/B2C) (MPAJADAJ)
Keywords
Where EndPoints is headquartered
LocationHeadquarters
- HQ city
- Bedford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
EndPoints business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Subscription and Membership: The Financial Times acquired a majority stake in Endpoints for its FT Specialist division, indicating a subscription-first revenue model typical of B2B publishing operations.
- Sponsored Content and Advertising: The website features sponsored posts and advertising opportunities through Endpoints Studio, generating revenue from pharma and biotech companies seeking to reach the publication's professional audience.
- Webinars and Events: Endpoints offers webinars and events as revenue-generating products, providing educational content to the biotech and pharma industry.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
EndPoints product offering
Product offeringCore offering
Endpoints News operates a B2B digital news publication covering the biotechnology and pharmaceutical industries, with editorial coverage of the science, people and money driving the biopharma sector. It organizes content across specialized topic hubs and editorial channels, and sells access via subscriptions, sponsored content, webinars, events, and a job board to biotech and pharma professionals, investors, and corporate strategy teams.
Product overview
Endpoints News is a biotech and pharma business news publication focused on the science, people and money that drive the industry. The core product is the Endpoints News website, which organizes content across 24 named editorial channels (including AI, Bioregnum, Biotech Voices, Cell/Gene Tx, Deals, FDA+, Financing, Pharma, R&D, Startups, and more) and 12 named topic hubs covering verticals such as AI drug discovery, antibody-drug conjugates, CRISPR and gene editing, GLP-1 drugs, and China biotech. Supplementary modules include Endpoints Webinars (webinar platform), Signal (biopharma sentiment index), IPO Tracker (market monitoring), Biopharma Jobs (career board), Endpoints Events, and Endpoints Studio (advertising/sponsorship). Endpoints News was acquired by the Financial Times as a majority stake for its FT Specialist division.
Differentiator
Problem solved
Functional benefit
Products and services
- Endpoints News The primary biopharma business news publication covering the science, people and money that drive the biotech and pharmaceutical industries, organized into 24 editorial channels and 12 topic-specific vertical hubs.
- Endpoints Webinars
Companies that use EndPoints
Customer profileSegments3 records
Ideal customer profiles3 records
EndPoints technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
EndPoints partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Financial Times (FT Specialist)flagshipThe Financial Times acquired a majority stake in Endpoints for its FT Specialist division in 2025. This acquisition aligns with the FT's strategy to expand B2B publishing operations and subscription-first revenue models. Endpoints became part of FT Specialist, joining the Financial Times' portfolio of professional information businesses.
Scale indicators1 record
Recent moves6 records
Expansion highlights6 records
EndPoints competitors and assessment
Company assessmentDirect peers
- STAT News: STAT is a leading digital news publication covering biotech, pharma, and health policy. It directly competes with Endpoints for the same scientist, executive, and investor audience on breaking biopharma news, with a similar subscription-plus-events revenue model.
- BioCentury: BioCentury is a long-standing subscription-based biopharma intelligence publication serving investors and corporate strategy teams. It competes with Endpoints on deep analysis of biotech business, financing, and dealmaking, and overlaps heavily on the investor/analyst reader segment.
- Fierce Biotech / Fierce Pharma: Fierce Biotech and Fierce Pharma (part of Questex) are daily biopharma news outlets covering R&D, regulation, and commercialization. They overlap directly with Endpoints on news coverage, email newsletters, and event sponsorships serving the same professional audience.
- BioSpace: BioSpace is a biopharma news and careers platform with topic hubs covering drug development, clinical trials, and industry jobs. It competes with Endpoints on biopharma news discovery, SEO, and the biopharma jobs board vertical.
- Genetic Engineering & Biotechnology News (GEN): GEN is a long-running biotech news publication covering R&D, drug discovery, and biotechnology tools. It overlaps with Endpoints on R&D, discovery, and AI drug discovery coverage for the same professional scientific audience.
- Endpoints competitors in trade pharma publishing: Pharmaceutical Executive is a B2B publication covering pharma commercialization, marketing, and policy. It competes with Endpoints on the Marketing channel coverage and overlapping pharma executive audience.
Broad incumbents
- Citeline / Pink Sheet (Informa): Citeline (formerly Pharma Intelligence) and the Pink Sheet are part of Informa's portfolio of pharma regulatory and business intelligence products. They overlap with Endpoints on biopharma regulatory coverage and serve overlapping pharma corporate strategy and investor audiences with deeper data products.
- Endpoints competitors — Evaluate Pharma: Evaluate (formerly EvaluatePharma) provides biopharma consensus forecasts, deals data, and industry analysis. It overlaps with Endpoints on biopharma M&A, financing, and IPO coverage, though positioned as a premium data vendor rather than a daily news outlet.
Emerging players
- MedCity News: MedCity News covers healthcare innovation, digital health, and life sciences business. It has partial overlap with Endpoints on biopharma business coverage, particularly the Health Tech channel, but covers a broader digital health audience.
Others
- Endpoints — Nikkei Biotechnology (sub-brand channel): Nikkei Biotechnology is a Japanese biopharma publication that licenses content through Endpoints News' Nikkei Biotechnology channel. It represents a cross-border content partnership comparable to other international biopharma intelligence publishers targeting Japan.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
EndPoints social profiles
Digital presenceEndPoints financial estimates
Financial estimateRevenue estimate
Valuation estimate
EndPoints leadership team
Management profileNumber of profiles
Profiles1 record
EndPoints funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EndPoints M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EndPoints
What does EndPoints do?
Endpoints News operates a B2B digital news publication covering the biotechnology and pharmaceutical industries, with editorial coverage of the science, people and money driving the biopharma sector. It organizes content across specialized topic hubs and editorial channels, and sells access via subscriptions, sponsored content, webinars, events, and a job board to biotech and pharma professionals, investors, and corporate strategy teams.
Is EndPoints a public or private company?
EndPoints is a private company. It is classified as corporate owned and is currently operating.
When was EndPoints founded?
EndPoints was founded in 1999. It employs 11 to 50 people.
Where is EndPoints based?
EndPoints is headquartered in Bedford, United States, in the North America region.
How does EndPoints make money?
Three revenue lines are on record. Subscription and Membership is the primary driver. The others are sponsored Content and Advertising and webinars and Events.
Who are EndPoints's main competitors?
Direct peers on record are STAT News, BioCentury, Fierce Biotech / Fierce Pharma, BioSpace, Genetic Engineering & Biotechnology News (GEN) and Endpoints competitors in trade pharma publishing. Broad incumbents are Citeline / Pink Sheet (Informa) and Endpoints competitors — Evaluate Pharma. MedCity News is listed as an emerging player. Endpoints — Nikkei Biotechnology (sub-brand channel) is listed as an others.
Does EndPoints have an API?
No public API is recorded for EndPoints.
What industry is EndPoints in?
EndPoints's product category is Biopharma Trade Media. Its primary akta.pro industry code is MPAJADAC, Business, Financial & Trade News Publishers, with a secondary code of MPAJADAJ, Newsletters & Email-Based News Publishers (B2B/B2C). Its NAICS code is 51312 and its SIC code is 2711.